SGLT2 Inhibitor and Urinary Tract Infection in Men at Risk for Voiding Dysfunction: A VigiBase Analysis.
SGLT2 抑制劑與有排尿功能障礙風險男性的尿路感染:VigiBase 分析。
Urol Pract 2024-09-06
The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study.
2型糖尿病患者使用SGLT2抑制劑尿路感染的發生率和危險因素:一項真實世界觀察性研究。
Medicines (Basel) 2022-12-27
Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?-a cross sectional analysis of a nationwide Japanese claims database.
鈉葡萄糖共同轉運蛋白-2抑制劑增加尿路感染嗎?-對全國日本索賠資料庫的橫斷面分析。
Endocr J 2023-12-01
SGLT2 抑制劑是治療糖尿病的藥物。研究指出,男性糖尿病患者使用這種藥物時,尿路感染(UTI)的風險較低。但對女性患者則無顯著影響。總結來說,SGLT2 抑制劑不會增加日本糖尿病患者患 UTI 的風險。
PubMedDOI
Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes.
SGLT-2 抑制劑與第二型糖尿病患者細菌性尿路感染的關聯。
BMC Endocr Disord 2023-11-22
Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System.
SGLT-2 抑制劑相關的尿路感染和生殖器真菌感染:美國FDA不良事件報告系統分析。
Expert Opin Drug Saf 2023-12-19
Concomitant Use of Sodium-Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection.
鈉葡萄糖共轉運輸體2抑製劑與過度活躍膀胱藥物的聯合使用及尿路感染風險。
Clin Pharmacol Ther 2024-04-22
Risk of Urogenital Bacterial Infection with Sodium-Glucose Cotransporter-2 Inhibitors: A Retrospective Cohort Study Using a Claims Database.
使用索引資料庫進行的回顧性世代研究:與鈉葡萄糖共同轉運蛋白-2抑制劑相關的泌尿生殖系細菌感染風險。
Diabetes Ther 2024-07-03
Genito Urinary Infection and Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Receiving SGLT2 Inhibitors: Evidence from a Systematic Literature Review of Landmark Randomized Clinical Trial.
接受 SGLT2 抑制劑治療的第二型糖尿病患者中的泌尿生殖感染和尿路感染:來自具有里程碑意義的隨機臨床試驗的系統文獻回顧證據。
Drug Res (Stuttg) 2024-07-11